Biogen Inc.

BIIB

US09062X1037

Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (17,2%) ; - other (9,1%): primarily revenues from partnership agreements.

Employees

7,570

Sector

Pharmaceuticals

Calendar

2024-10-21 - Q3 2024 Earnings Release (Projected)

Related indices

S&P 500

More about the company

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

200.64USD

Average target price

271.42USD

Spread / Average Target

+35.28%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 04:00:00 2024-09-10 pm EDT			5-day change	1st Jan Change
200.64 ^USD	+0.69%		-2.01%	-22.46%

Sep. 10	C4 Therapeutics Delivers Final Development Candidate Under Biogen Deal	MT
Sep. 04	Transcript : Biogen Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 10:00 AM

C4 Therapeutics Delivers Final Development Candidate Under Biogen Deal	Sep. 10	MT
Transcript : Biogen Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 10:00 AM	Sep. 04
Biogen Says Trial of Potential Treatment for Infant Spinal Muscular Atrophy Meets Primary Endpoint	Sep. 04	MT
Eisai and Biogen's Alzheimer's Drug Leqembi Receives MHRA Approval in Great Britain	Aug. 22	MT
Sector Update: Health Care Stocks Flat to Higher Premarket Thursday	Aug. 22	MT
Biogen, Eisai's Alzheimer's Drug Deemed Too Costly for UK National Health Service	Aug. 22	MT
Biogen, Eisai's Mild Dementia Treatment Gets Marketing Authorization From UK Regulatory Authority	Aug. 22	MT
Biogen: UK marketing authorization for Alzheimer's disease	Aug. 22	CF
UK patients unlikely to get access to Eisai-Biogen's Alzheimer's drug	Aug. 22	RE
Incyte's blood cancer drug succeeds late-stage trial	Aug. 15	RE
Biogen Inc. Enters Credit Agreement with Bank of America, N.A	Aug. 14	CI
BioArctic Says UAE Approves Leqembi as Alzheimer's Disease Treatment	Aug. 14	MT
Can calm follow last week's rollercoaster?	Aug. 12
Xbrane Biopharma to Out-License Two Biosimilar Candidates for Financing Purposes	Aug. 12	MT
Analyst recommendations: Biogen, Cloudflare, Doordash, Moderna, Diageo...	Aug. 12
Canaccord Genuity Adjusts Biogen Price Target to $298 From $308, Maintains Buy Rating	Aug. 06	MT
Mizuho Adjusts Biogen's Price Target to $251 From $277, Keeps Outperform Rating	Aug. 05	MT
Truist Adjusts Biogen's PT to $302 From $340, Maintains Buy Rating	Aug. 05	MT
Morgan Stanley Adjusts Price Target on Biogen to $291 From $311	Aug. 02	MT
Barclays Adjusts Price Target on Biogen to $190 From $200	Aug. 02	MT
Leerink Adjusts Price Target on Biogen to $310 From $350	Aug. 02	MT
Goldman Sachs Adjusts Price Target on Biogen to $320 From $342	Aug. 02	MT
Wells Fargo Adjusts Price Target on Biogen to $225 From $240	Aug. 02	MT
Needham Adjusts Price Target on Biogen to $285 From $288	Aug. 02	MT
Scotiabank Adjusts Price Target on Biogen to $244 From $275	Aug. 02	MT

Biogen Inc.

Equities